Psoriasis

PsO · Immunology · 14 drugs · 4 indications

Chronic autoimmune skin disease affecting ~2-3% of the global population (~125M people). The immune system attacks skin cells, causing them to multiply 10x faster than normal, forming raised, red, scaly plaques. Most common form is plaque psoriasis (~80-90%). ~30% also develop psoriatic arthritis. The IL-23/IL-17 axis is the key driver: IL-23 signals Th17 cells to produce IL-17A and IL-17F, which directly cause keratinocyte hyperproliferation. Biologic drugs targeting IL-23 (Skyrizi, Tremfya) or IL-17 (Bimzelx, Cosentyx, Taltz) have transformed treatment. Global psoriasis biologic market >$30B. Key dynamics: IL-23 blockers = best durability and safety; IL-17A+F (Bimzelx) = fastest/deepest clearance with candida risk; oral IL-23R antagonist (icotrokinra, JNJ) filed 2025 could disrupt injectable market.

Competitive Landscape (14 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Icotrokinra	—	IL-23 receptor antagonist (oral peptide)	Peptide	Oral	FILED
Zasocitinib	—	TYK2 inhibitor	Small molecule	PO	PHASE3
Sonelokimab	—	IL-17A/F inhibitor	Biologic (nanobody)	SC	PHASE3
Cosentyx	NVS	IL-17A inhibitor	Antibody	SC	APPROVED
Cimzia	UCB	TNF inhibitor	Antibody	SC	APPROVED
Bimzelx	UCB	IL-17A/F inhibitor	Antibody	SC	APPROVED
Taltz	LLY	IL-17A inhibitor	Antibody	SC	APPROVED
Skyrizi	ABBV	IL-23 inhibitor	Biologic	IV/SC	APPROVED
Humira	ABBV	TNF inhibitor	Antibody	SC	APPROVED
Otezla	AMGN	PDE4 inhibitor (oral)	Small molecule	Oral	APPROVED
Enbrel	AMGN	TNF inhibitor (fusion protein)	Fusion protein	SC	APPROVED
Stelara	—	IL-12/23 inhibitor	Biologic (mAb)	SC	APPROVED
Sotyktu	—	TYK2 inhibitor	Small molecule	Oral	APPROVED
Tremfya	—	IL-23p19 inhibitor	Biologic	IV/SC	APPROVED

Indications (4)

Plaque psoriasis

Cimzia APPROVEDBimzelx APPROVEDOtezla APPROVEDEnbrel APPROVED

Moderate-to-severe plaque psoriasis

Cosentyx APPROVEDZasocitinib PHASE3Skyrizi APPROVEDHumira APPROVEDStelara APPROVEDSotyktu APPROVEDIcotrokinra FILEDTremfya APPROVEDBimzelx APPROVEDTaltz APPROVEDSonelokimab PHASE2

Pediatric plaque psoriasis

Bimzelx PHASE3

Psoriasis

Taltz APPROVED

Upcoming Catalysts

Skyrizi - Psoriasis - H2H vs DeucravacitinibCLINICAL

ABBV2026

Icotrokinra - Mod-sev PsO - FDA PDUFA DecisionREGULATORY

JNJQ2 2026 (est. April-June 2026)

Bimzelx - Commercial Momentum UpdatesCOMMERCIAL

UCB2026

Bimzelx vs Risankizumab - PsA - Head-to-Head DataCLINICAL

UCBH2 2026

Taltz + Zepbound - PsA/Obesity - FDA FilingREGULATORY

LLYH2 2026

Cosentyx - Biosimilar Competition TimelineCOMPETITIVE

NVSOngoing

Data from Supabase · Updated 2026-03-24